Aslan Pharmaceuticals and Array BioPharma Enter into License Agreement for Cancer Drug

Singapore-based Aslan Pharmaceuticals and Array BioPharma have signed a license agreement to develop Array’s cancer drug called ARRY-543.

Drug developer Aslan Pharmaceuticals and Biopharmaceutical company Array BioPharma have signed a license agreement to develop Array’s HER2/EGFR inhibitor, ARRY-543, currently in Phase II development for solid tumors.

Aslan will fund development through proof-of-concept, targeting gastric cancer in a development program conducted in Asia. Aslan will then find a global partner for Phase III development and commercialization and will share a portion of the proceeds.

"Our partnership with Aslan provides a great opportunity to fund and advance the development of ARRY-543,” said Robert E. Conway, chief executive officer of Array BioPharma. “Aslan’s creative development strategy of leveraging Asia to conduct clinical development is particularly compelling for A